<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cells from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> display <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> proliferative responses to transforming growth factor beta (TGF beta) </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed growth inhibition and SMAD2 phosphorylation by TGF beta in CD34+ cells from nine patients, as compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="2" pm="."><plain>While TGF beta consistently inhibited <z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation of <z:mpath ids='MPATH_458'>normal</z:mpath> cells (41% of control, P &lt; 0.05), cells from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were growth-inhibited in only four of seven cases (40%), whereas TGF beta stimulated <z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation in the three other samples (166%) </plain></SENT>
<SENT sid="3" pm="."><plain>Remarkably, TPO reverted the stimulatory effect of TGF beta to profound growth inhibition </plain></SENT>
<SENT sid="4" pm="."><plain>Upon exposure to TGF beta, SMAD2 protein was phosphorylated in <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cells (n = 3), CD34+ leukemic blasts from <z:hpo ids='HP_0000001'>all</z:hpo> examined patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 4), and in the myeloid leukemic cell lines M-07e and HEL </plain></SENT>
<SENT sid="5" pm="."><plain>TGF beta inhibited TPO-mediated <z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation, cell proliferation and survival in <z:hpo ids='HP_0000001'>all</z:hpo> samples analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>In M-07e cells and CD34+ cells from healthy donors, this inhibition was enhanced by an <z:chebi fb="68" ids="48706">antagonist</z:chebi> of JAK2 (AG490), but not a MEK-1 antagonist (PD098059) </plain></SENT>
<SENT sid="7" pm="."><plain>Conversely, in CD34+ cells from a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, both AG490 and PD098059 significantly enhanced TGF beta-mediated suppression of TPO-induced <z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, altered responses to TGF beta may be due to defects downstream of SMAD2 and may involve MAPK activation </plain></SENT>
</text></document>